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OBJECTIVES We investigated the association of the heme oxygenase-1 (HO-1) promoter genotype with
the inflammatory response and restenosis after balloon angioplasty.
BACKGROUND Heme oxygenase-1, which is induced by balloon angioplasty, can inhibit neointima formation
and vascular remodeling. A dinucleotide repeat in the HO-1 gene promoter shows a length
polymorphism that modulates HO-1 gene transcription. Short (25 guanosine thymidine
[GT]) repeats are associated with a 10-fold greater up-regulation of HO-1 than are longer
repeats.
METHODS We studied 381 consecutive patients who underwent femoropopliteal balloon angioplasty (n
 210) and comparison groups with femoropopliteal stenting (n  68) and lower limb
angiography (n 103). C-reactive protein (CRP) was measured at baseline, 24, and 48 h. We
evaluated patency at six months by duplex sonography and assessed the association of the
length of GT repeats in the HO-1 gene promoter with postintervention CRP and restenosis.
RESULTS Restenosis within six months was found in 74 patients (35%) after balloon angioplasty and in
21 patients (31%) after stenting. After balloon angioplasty, carriers of the short length (25
GT) dinucleotide repeats had a lower postintervention CRP at 24 h (p  0.009) and 48 h (p
 0.001) and a reduced risk for restenosis (adjusted relative risk 0.43, 95% confidence
interval: 0.24 to 0.71, p  0.001) compared with patients with longer alleles. After stenting
or angiography, we found no association between the HO-1 genotype with CRP or
restenosis.
CONCLUSIONS The HO-1 promoter genotype that controls the degree of HO-1 up-regulation in response
to stress stimuli is associated with the postintervention inflammatory response and the
restenosis risk after balloon angioplasty. (J Am Coll Cardiol 2004;43:950–7) © 2004 by the
American College of Cardiology Foundationd
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lnderstanding the inherited factors that influence a pa-
ient’s susceptibility for restenosis after successful revascu-
arization by femoropopliteal percutaneous transluminal an-
ioplasty (PTA) may lead to better therapies (1–5).
owever, specific candidate genes have not yet been iden-
ified. Heme oxygenase-1 (HO-1) is a novel vascular pro-
ective factor with potent anti-inflammatory and anti-
xidant effects and the ability to inhibit the proliferation of
mooth muscle cells (SMCs) and reduce negative vascular
emodeling (6–11). Development of restenosis in large
easure involves these very factors that are inhibited by
O-1: inflammation in the vessel wall, constrictive vascular
emodeling, and hypertrophic neointima formation through
MC proliferation (12–14).
Heme oxygenase-1 is up-regulated by balloon angio-
lasty. However, humans may differ quantitatively in their
bility to mount an HO-1 response. There is a length
olymorphism in the form of a guanosine thymidine (GT)n
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o this work.
Manuscript received July 3, 2003; revised manuscript received September 11, 2003,Cccepted September 29, 2003.inucleotide repeat in the 5-flanking region of the human
O-1 gene that modulates the quantitative level of HO-1
ctivity in response to a given stimulus (15,16). We hypoth-
sized that the ability of a patient to respond strongly in
erms of up-regulating HO-1 may be important in protec-
ion from restenosis.
Short (25 GT) dinucleotide repeats in the HO-1 gene
romoter show highly significant up-regulation of HO-1 to
nflammatory stimuli; longer dinucleotide repeats, in con-
rast, have relatively low HO-1 inducibility (16). We pre-
iously found an association between short (GT)n dinucle-
tide repeats (higher HO-1 induction) and a reduced rate of
ntermediate-term restenosis (7). However, the results of
hat study suffered from the fact that the study was a
etrospective analysis, that few patients were evaluated, and
hat other factors that play a role in restenosis, such as the
nflammatory response, were not evaluated. Thus, we
resent here a larger and prospective patient study. Given
he known anti-inflammatory action of HO-1, we also
sked whether an association exists between the HO-1
enotype and an attenuation of the inflammatory vessel wall
esponse. Thus, the aims of the present prospective study
ere to assess whether carriers of short length (GT)n
inucleotide repeats in the HO-1 gene promoter exhibit a
ower postintervention inflammatory response measured by
-reactive protein (CRP) serum levels and a lower fre-
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March 17, 2004:950–7 HO-1 and Restenosis After Peripheral PTAuency of restenosis at six months after femoropopliteal
alloon angioplasty. As comparison groups, we studied
atients with peripheral artery disease who underwent
emoropopliteal stenting or had a lower limb intra-arterial
igital subtraction angiography without percutaneous inter-
ention during the same time interval. The stenting group
as included to comparatively study a mechanism of reste-
osis different from the mechanism arising after angioplasty;
he angiography group was studied to assess whether the
O-1 promoter genotype is associated with the non-
pecific systemic inflammatory response after angiography.
ETHODS
tudy design. This study was designed as a prospective
ohort study. We enrolled all consecutive inpatients with
eripheral artery disease (PAD) Fontaine stage IIa, IIb, III,
nd IV who underwent primary successful femoropopliteal
alloon angioplasty, femoropopliteal stenting, or lower limb
ngiography during a 12-month study period at the angi-
logy department of a tertiary care university hospital.
atients who underwent primary thrombolysis were not
ligible for the study. The study was approved by the local
eview board and ethics committee. All patients gave their
ritten informed consent.
efinitions. The diagnosis of PAD was assessed by clinical
valuation, ankle brachial index measurements, and duplex
onography, and it was confirmed by lower limb angiogra-
hy in all patients. Primary technical success was defined as
remaining diameter reduction 30% at the treated seg-
ent in the final angiogram. Residual stenosis in patients
ith primary technical success, indicating a successful but
uboptimal result, was defined as a remaining absolute
tenosis of 10% to 30% at the treated segment in the final
ngiogram. Poor run-off was defined as either occlusion or
ignificant stenosis of the femoral or popliteal artery distal to
he treated segment and/or in patients with occlusion or
ignificant stenosis of at least two crural arteries. Restenosis
as defined as 50% diameter reduction at the dilated
egment of the vessel within the first six months after PTA.
olor-coded duplex sonography (5-MHz, linear array color
Abbreviations and Acronyms
CI  confidence interval
CO  carbon monoxide
CRP  C-reactive protein
GT  guanosine thymidine
HO-1  heme oxygenase-1
IQR  interquartile range (range from the 25th to the
75th percentile)
PAD  peripheral artery disease
PSV  peak systolic velocity
PTA  percutaneous transluminal angioplasty
RR  risk ratio
SMC  smooth muscle cellrobe [model XP 10; Acuson, Mountain View, California]) las used for categorization of restenosis (7,17). The peak
ystolic velocity (PSV) in the dilated region was determined
nd compared with the PSV in the preceding normal
egment. A focal increase in the PSV of at least 140%
corresponding to a peak velocity ratio of 2.4) was
onsidered indicative of a stenosis of50% at that site (18).
atient data. Two independent observers recorded pa-
ients’ medical history and data from physical examination
y a standard questionnaire at admission. Data were
hecked for inter-observer agreement at the day of patients’
ischarge; in case of discrepancies, the patient was re-
valuated by both investigators. Antecubital venous blood
amples for determination of CRP were taken at baseline
efore the intervention, 24 h, and 48 h after the interven-
ion. We used a high-sensitivity assay (N Latex CRP Mono,
ADE Behring, Vienna, Austria) with a lower detection
evel of 0.03 mg/dl and a coefficient of variation of 4.6% for
easurement of serum CRP levels.
nterventions. Two experienced interventionists per-
ormed all procedures after a standard protocol. Patients
eceived 5,000 IU heparin intra-arterially after placement of
he arterial sheath. We recorded the duration of fluoroscopy
nd dose of contrast agent (the nonionic, low-osmolality
ontrast agent Optiray 320 [Mallinckrodt, St. Louis, Mis-
ouri]). Location, degree, and length of the stenosis or
cclusion as well as vessel size at the non-diseased segment
roximal to the lesion were documented. The balloon
iameter for subsequent angioplasty corresponded to the
roximal non-diseased vessel diameter. Stent implantation
all self-expanding Easy Wallstents, Boston Scientific,
atick, Massachusetts) was performed as a bail-out proce-
ure only in cases with a primary failure of balloon angio-
lasty due to a remaining absolute stenosis above 30% at the
ilated segment. The technical results of PTA in terms of
nitial technical success, post-procedural residual stenosis,
nd number of run-off vessels were derived from the final
ngiograms.
One medical technical assistant performed color-coded
uplex sonography, ankle brachial index, and oscillography
4 h after PTA for documentation of prolonged technical
uccess or early restenosis. Peri-intervention and postinter-
ention complications at the site of arterial puncture and at
he dilated vessel segment were documented up to 48 h after
he intervention. All patients received anti-thrombotic
edication with acetyl salicylic acid 100 mg daily during the
hole study period. Patients with stent implantation addi-
ionally received clopidogrel 75 mg daily for eight weeks
ostintervention, starting with a loading dose of 300 mg
mmediately after stent implantation. All patients routinely
eceived once daily low dose low molecular weight heparin
or three days starting 8 h postintervention. Glycoprotein
Ib/IIIa antagonists were not given in any patient.
O-1 genotype assessment. Genomic DNA was isolated
rom whole blood using standard techniques. Polymerase
hain reaction amplifications of the HO-1 (GT)n repeat
ength polymorphism was performed as described (7). Two
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HO-1 and Restenosis After Peripheral PTA March 17, 2004:950–7ndependent observers who were blinded with regard to
atients’ clinical data evaluated the dinucleotide repeat
ength. We divided allelic repeats into two subclasses after a
lassification based on transfection studies with low and
igh GT repeats (16): short repeats, with 25 (GT)n were
esignated as allele class S (short), and longer repeats with
25 (GT)n as allele class L (long).
ollow-up for restenosis. Patients were reinvestigated by
ix months after the procedure in the outpatient clinic to
nalyze the occurrence of restenosis: we performed duplex
onography, ankle brachial index, oscillography, evaluation
f patient complaints, and physical re-examinations rou-
inely in all patients. Ipsilateral follow-up angiograms for
onfirmation of the duplex findings were obtained in 132
atients (63%) after balloon angioplasty and in 45 patients
fter stent implantation (66%). Agreement for a 50%
estenosis was 92% between duplex sonography and angiog-
aphy in the balloon angioplasty group and 93% in the
tenting group. Two independent observers, who were
linded with regard to patients’ HO-1 genotype, evaluated
he follow-up data.
tatistical analysis. Continuous data are given as median
nd interquartile range (IQR from the 25th to the 75th
ercentile). Categorical data are given as counts and fre-
uencies. Chi-square tests were used to compare groups of
ategorical data. The Mann-Whitney U test was used to
ompare unpaired continuous data. Friedman tests were
sed to analyze repetitive measurements of CRP levels. The
edian and its 95% confidence interval (CI) for serum CRP
ere calculated according to a standard formula (19). We
sed analysis of covariance to assess the association between
O-1 genotype and CRP levels at 24 and 48 h after balloon
ngioplasty and to account for the baseline value of CRP. As
erum CRP was skewed to the right, we used log transfor-
ation to achieve a distribution resembling a normal
istribution. The resulting effect size and the corresponding
5% CI was back-transformed. This means that the effect
epresents the ratio of serum CRP in non-carriers of the
lass S allele to serum CRP in carriers of the class S allele in
he HO-1 gene promoter, clinically still a useful measure.
ultivariate logistic regression analysis was applied to assess
he independent effect of the HO-1 genotype (being a
arrier of the class S allele) on six months patency while
djusting for the potentially confounding effects of other
aseline variables. Baseline variables were selected for the
odel if they: 1) had either a clinically plausible relation
ith the outcome according to the TransAtlantic Inter-
ociety Consensus recommendations (1); or 2) appeared to
e imbalanced between the HO-1 genotypes indicated by a
alue p  0.20. We used a hierarchical modeling strategy to
ssess the effect of demographic variables and of procedure-
elated variables separately and jointly. As the outcome was
frequent event, we converted the odds ratios derived from
he multivariate model to risk ratios (RR) and the 95% CI
sing a standard formula (20). A two-sided p value 0.05
as considered as statistically significant. Calculations were terformed with Stata, release 7 (Stata, College Station,
exas), StatXact 5 (Cytel Software, Cambridge, Massachu-
etts) and SPSS for Windows (Version 10.0, SPSS Inc.,
hicago, Illinois).
ESULTS
tudy population. We evaluated 414 patients for the study
ithin a 12-month period. Femoropopliteal balloon angio-
lasty was performed in 237 patients, femoropopliteal stent-
ng in 71 patients, and lower limb angiography in 106
atients. In the balloon angioplasty group, the primary
echnical success rate was 96% (n  224 of 237), 2 of 237
atients (1%) were lost to follow-up, and in 12 of 237
atients (5%), material for genetic analysis was missing. In
he stenting group, the primary technical success rate was
00% (n  71 of 71), 3 of 71 patients (4%) were lost to
ollow-up, and genetic data were complete. In the angiog-
aphy group, 3 of 106 patients (3%) had missing material for
enetic analysis. Therefore, we had to exclude 33 of 414
atients (8%) from the final analysis, which was based on
ata from 381 patients (92%): 210 patients in the balloon
ngioplasty group, 68 patients after stenting, and 103
atients with peripheral angiography. Median age in the
alloon angioplasty, stenting, and angiography groups was
2 years (IQR, 63 to 78), 68 years (IQR, 57 to 74), and 67
ears (IQR, 58 to 74), respectively, with 98 (47%), 42
62%), and 65 (63%) males.
O-1 genotype. Genotype frequencies of homozygous
lass S allele carriers (S/S), heterozygous class S allele
arriers (S/L), and class S allele non-carriers (L/L) were 7%
n  14), 47% (n  99), 46% (n  97) in the balloon
ngioplasty group, 7% (n 5), 35% (n 24), 57% (n 39)
n the stenting group, and 5% (n  5), 43% (n  44), 52%
n  54) in the angiography group, respectively (p  0.37).
o significant differences of the class S allele frequency was
bserved between the groups of balloon angioplasty (n 
13, 54%), stenting (n  29, 43%), and angiography (n 
9, 48%), respectively (p  0.23).
ostintervention inflammatory response after balloon
ngioplasty. The CRP levels increased at 24 h and 48 h
fter balloon angioplasty (p  0.001), indicating an acute
nflammatory response. The HO-1 genotype was associated
ith postintervention CRP serum levels in the balloon
ngioplasty group: carriers of the class S alleles had lower
ostintervention CRP serum levels compared with non-
arriers of the class S allele (Fig. 1). At 24 h, CRP levels of
on-carriers of the class S allele were 1.46  the CRP level
f class S allele carriers (95% CI: 1.14 to 1.88, p  0.009)
hen adjusting for baseline CRP values; at 48 h, the
aseline-adjusted ratio of CRP levels for non-carriers versus
arriers of the class S allele was 1.70 (95% CI: 1.30 to 2.24,
 0.001). We found no association between the HO-1
enotype and postintervention CRP levels in the compari-
on group after lower limb angiography (Fig. 1). Comparing
he postintervention course of CRP in patients after angiog-
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March 17, 2004:950–7 HO-1 and Restenosis After Peripheral PTAaphy and PTA, patients after PTA and patients after
ngiography who were carriers of the class S allele showed a
omparable CRP increase. In contrast, non-carriers of the
lass S allele exhibited a significantly higher CRP increase
fter PTA than did carriers of the class S allele and patients
fter angiography (Fig. 1).
ostintervention inflammatory response after stenting.
-reactive protein levels increased at 24 h and 48 h after
tenting (p  0.001), also indicating an acute inflammatory
esponse after the procedure. However, no significant asso-
iation between the HO-1 genotype and postintervention
RP was found at 24 h (p  0.70) or 48 h (p  0.31).
estenosis after balloon angioplasty. Seventy-four pa-
ients (35%) after balloon angioplasty had restenosis of the
reated vessel segment by six months after presentation.
atients with restenosis had higher postintervention CRP
evels at 24 h (1.26 mg/dl; IQR, 0.77 to 2.26) and 48 h (2.06
g/dl; IQR, 1.06 to 3.69) compared with patients without
estenosis (24 h 0.80 mg/dl, IQR 0.34 to 1.75, p  0.001;
8 h 0.97, IQR 0.64 to 2.08, p  0.001).
The allele frequencies of the (GT)n microsatellite in the
O-1 promoter region of patients with and without reste-
osis are shown in Figure 2. The HO-1 genotype was
ssociated with the occurrence of restenosis; 14 patients who
ere homozygous class S allele carriers had the lowest rate
f restenosis, whereas heterozygous class S patients had a
radually increased restenosis rate, and homozygous L
arriers exhibited the highest recurrence rates (Fig. 3).
We performed an univariate comparison between carriers
nd non-carriers of the class S allele to identify possible
onfounding factors (Table 1). Due to the small number of
omozygous class S allele carriers, homozygous and het-
rozygous patients were grouped and analyzed together.
emographic data and clinical characteristics were highly
imilar between class S carriers and non-carriers, although
arriers of the class S allele were more frequently smokers,
nd non-carriers had a slightly higher incidence of coronary
rtery disease. The procedure-related variables: “length of
he treated lesion” and “poor run-off” also showed a trend
igure 1. Course of C-reactive protein (median and 95% confidence
nterval of the median) from baseline to 48 h postintervention after
emoropopliteal balloon angioplasty (n  210) and after lower limb
ngiography (n 103). Carriers and non-carriers of the class S allele in the
eme oxygenase-1 (HO-1) gene promoter were compared. PTA 
ercutaneous transluminal angioplasty. Diamonds  carriers of the class S
llele; squares  non-carriers of the class S allele.owards a difference between the two groups (Table 1). We when applied a multivariate logistic regression model to
ssess the effect of the HO-1 genotype on patency by six
onths after PTA adjusting for potentially confounding
ffects. Carriers of the class S allele in the HO-1 gene
romoter had a very significantly reduced risk for restenosis
t six months (relative risk 0.43, 95% CI: 0.24 to 0.71, p 
.001) adjusting for sex, age (years), smoking (yes vs. no),
iabetes mellitus (yes vs. no), Fontaine stage (IIa to IV),
ength of lesion (quartiles), residual stenosis after PTA (yes
s. no), poor run-off (yes vs. no), and intimal dissection (yes
s. no) (Table 2).
To evaluate the extent to which CRP levels are an
ntermediate on the association between the HO-1 geno-
ype and restenosis within six months, we further calculated
wo fully adjusted models including CRP values at 24 or
8 h (quartiles). The association between the HO-1 gene
olymorphism and restenosis was slightly attenuated when
igure 2. Frequency distribution of the guanosine thymidine (GT)n
epeats in patients with and without restenosis after femoropopliteal
alloon angioplasty (n  210): lower number of (GT)n repeats in patients
ithout restenosis compared with patients with restenosis (p  0.001).
igure 3. Lower restenosis rates after femoropopliteal balloon angioplasty
n homozygous and heterozygous class S allele carriers compared with
on-carriers of the class S allele in the heme oxygenase-1 gene promoter (p
0.001). Bars indicate percentage of patients with and without restenosis
ccording to the heme oxygenase-1 (HO-1) promoter genotype; point
stimates and 95% confidence interval indicate the percentage of patients
ith restenosis for each HO-1 promoter genotype.
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HO-1 and Restenosis After Peripheral PTA March 17, 2004:950–7ntering CRP levels measured at 24 h to the final model
RR 0.45, 95% CI: 0.24 to 0.76, p 0.001) and was further
educed when using the 48 h CRP values (relative risk 0.53,
5% CI: 0.28 to 0.89, p  0.012). However, because the
O-1 polymorphism certainly affects the risk of restenosis
hrough multiple inflammatory mechanisms, the attenua-
ion was not complete.
estenosis after stenting. In-stent restenosis within six
onths was found in 21 of 68 patients (31%). We found no
ssociation between the HO-1 genotype and six months
estenosis after femoropopliteal stenting: class S carriers had
similar rate of in-stent restenosis compared with non-
arriers of the class S allele (8 of 29, 28% vs. 13 of 39, 33%,
 0.61).
Table 1. Comparison of Carriers Versus Non-
Oxygenase-1 Gene Promoter in 210 Patients A
Median age in yrs (IQR)
Male gender
Arterial hypertension
Hyperlipidemia
Smoking
Diabetes mellitus
Coronary artery disease
Carotid stenosis 25%
Fontaine stage of PAD
IIa
IIb
III
IV
Recurrent stenosis after prior PTA
Complete vessel occlusion
Median grade of stenosis in % (IQR)
Median length of lesion in mm (IQR)
Vessel size proximal to the lesion in mm (IQR)
Residual stenosis
Poor run-off
Initimal dissection
IQR  interquartile range; PAD  peripheral artery disease
Table 2. Logistic Regression Model Assessing
Oxygenase-1 Genotype “Carrier of the Class S
Patients After Femoropopliteal Balloon Angiop
Ris
Model I (univariate)
Carriers of the class S allele
Model II (adjusted for demographic
baseline variables*)
Carriers of the class S allele
Model III (adjusted for procedure-related
variables†)
Carriers of the class S allele
Model IV (adjusted for demographic and
procedure-related variables‡)
Carriers of the class S allele
Class S allele denotes 25 (GT)n repeats in the heme oxygen
no), smoking (yes vs. no), Fontaine stage (IIa to IV); †length
vs. no), initimal dissection (yes vs. no); ‡variables of model II andISCUSSION
e found that the HO-1 promoter genotype was associated
ith the occurrence of restenosis after femoropopliteal
alloon angioplasty. Patients with short repeats [S allele:
25 (GT)n] in the HO-1 gene promoter exhibited a lower
ostintervention inflammatory response and a lower reste-
osis rate at six months compared with patients with longer
L alleles:25 (GT)n] repeats. This suggests that a stronger
O-1 response, which is associated with the short GT
epeats, is protective against restenosis as compared with the
ower HO-1 response in the absence of the class S allele.
odulation of the postintervention vascular inflammatory
esponse seems to be an underlying mechanism of the
ers of the Class S Allele in the Heme
Femoropopliteal Balloon Angioplasty
riers of the
ss S Allele
 113)
Non-Carriers of
the Class S Allele
(n  97) p Value
(61 to 78) 73 (66 to 78) 0.37
(58%) 46 (47%) 0.11
(81%) 70 (72%) 0.19
(83%) 74 (76%) 0.21
(35%) 22 (23%) 0.060
(45%) 48 (50%) 0.53
(46%) 54 (56%) 0.17
(56%) 50 (52%) 0.54
0.63
(7%) 6 (6%)
(61%) 65 (67%)
(12%) 7 (7%)
(20%) 19 (20%)
(26%) 33 (34%) 0.17
(24%) 24 (25%) 0.89
(80 to 95) 90 (80 to 99) 0.38
(30 to 90) 40 (30 to 80) 0.091
(4 to 6) 5 (4 to 6) 0.86
(54%) 57 (59%) 0.49
(14%) 23 (24%) 0.076
(18%) 18 (19%) 0.87
 percutaneous transluminal angioplasty.
ndependent Association of the Heme
le” and Restenosis at Six Months in 210
io 95% Confidence Interval p Value
0.33–0.78 0.001
0.28–0.74 0.001
0.28–0.76 0.001
0.24–0.71 0.001
gene promoter. *Gender, age (yrs), diabetes mellitus (yes vs.
on (quartiles), residual stenosis (yes vs. no), poor run-off (yesCarri
fter
Car
Cla
(n
71
66
91
94
39
51
52
63
8
69
14
22
29
27
90
60
5
61
16
20the I
Alle
lasty
k Rat
0.52
0.47
0.48
0.43
ase-1
of lesimodel III.
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March 17, 2004:950–7 HO-1 and Restenosis After Peripheral PTAeneficial effects of HO-1 up-regulation after balloon an-
ioplasty. These findings in the present patient sample are
n concert with former preliminary and retrospective data in
smaller patient sample from our group (7) and suggest that
he HO-1 functional polymorphism may have an important
nfluence on the pathophysiology of restenosis after balloon
ngioplasty.
Heme oxygenase is the rate-limiting enzyme in the
atabolism of heme into biliverdin (which is rapidly con-
erted to bilirubin), free iron (which induces the up-
egulation of ferritin), and CO. Vascular SMCs and endo-
helial cells can express HO-1, the inducible isoform of
O, which has potent anti-inflammatory and anti-oxidant
apacity (21). Heme oxygenase-1 exerts its protective effects
ia the products generated after the action of HO-1 on
eme. All three products can be protective. Carbon mon-
xide exerts potent anti-proliferative (of SMCs) and anti-
nflammatory effects (of endothelial cells) in the vascular
all and, thereby, influences neointima formation, SMC
ctivation, and vascular remodeling (21–25). In addition,
O suppresses the pro-inflammatory while boosting the anti-
nflammatory response of monocytes to lipopolysaccharide
21). Ferritin has a potent anti-apoptotic effect in endothe-
ial cells as well as protecting cells from the injurious effects
f free iron. Bilirubin is a known anti-oxidant that also has
nti-apoptotic effects.
Balloon angioplasty induces vascular injury manifested by
n inflammatory response and subsequent cell proliferation
f vascular SMCs (26–30). The postintervention course of
cute phase reactants reflects the extent of vascular inflam-
ation at the site of the treated segment after percutaneous
atheter interventions. In particular, serum CRP is a sensi-
ive, specific, and fast-reacting marker of the acute phase
eaction that provides an indirect measure of the cytokine-
ependent inflammatory process in the arterial wall (31).
igher CRP levels indicate enhanced vascular inflamma-
ion. In this context, CRP was shown to predict restenosis
fter femoropopliteal PTA (32). Consistently, in the present
tudy, patients who experienced restenosis had higher
ostintervention CRP levels compared with patients with
atent vessels at six months. Both damage to endothelial
ells during balloon dilation and potentially physical strain
n the vessel wall likely modulate the level of gene expres-
ion in activated vascular SMCs and endothelial cells and
mplify the proliferative phase of vessel repair (33). A
rotective response by means of up-regulation of genes that
uppress the pro-inflammatory process after endothelial
njury has been suggested earlier (34,35). Heme
xygenase-1 has been a prime candidate for a vascular
rotective gene in this regard (6,7,35,36).
A (GT)n dinucleotide repeat in the 5 flanking region of
he human HO-1 gene is highly polymorphic and modu-
ates HO-1 gene expression (16,37). A major strength of the
resent study is its confirmation that the 5-flanking poly-
orphism in the HO-1 gene is significantly associated withhe restenosis after PTA in a prospective study on an independent patient sample and its demonstration of an
ssociation between CRP levels as a measure of postinter-
ention inflammatory response and the HO-1 genotype.
hese findings, which are in concert with experimental
ndings in rodents in which HO-1 is induced and shown to
rotect from intimal hyperplasia, strongly support HO-1 as
relevant factor in the pathogenesis of restenosis and as an
nti-inflammatory factor in general. The differential induc-
ion of HO-1, which is almost certainly correlated with
ifferential production of CO and the other products of
O-1 action on heme, may account for the inhibition of
xcessive proliferation of vascular SMCs, constrictive neo-
ntimal hyperplasia, and recurrent lumen narrowing due to
egative vascular remodeling (6,38). Nevertheless, it cannot
e ruled out that mechanisms other than an anti-
nflammatory action of HO-1 are operative as well, like a
irect anti-proliferative effect of CO on vascular SMCs.
Cautious interpretation of the present findings suggests
n additive or “gene-dose” effect of the HO-1 gene poly-
orphism; 14 patients who were homozygous class S allele
arriers had the lowest rate of restenosis, whereas heterozy-
ous class S patients had a gradually increased restenosis
ate, and homozygous L carriers exhibited the highest rates
f recurrences (Fig. 3).
In patients with stent implantation, no association be-
ween the HO-1 genotype, vascular inflammation, and
estenosis was found. Restenosis after stenting is mainly due
o in-stent neointimal hyperplasia (39,40), whereas, after
alloon angioplasty, negative vascular remodeling plays a
ajor role in the development of restenosis. This suggests
hat the mechanism responsible for the beneficial effect of
O-1 after balloon angioplasty is due to an attenuation of
egative remodeling rather than an inhibition of neointimal
yperplasia, otherwise one would expect an association of
he HO-1 genotype also with in-stent restenosis. However,
o confirm this hypothesis, data from intravascular ultra-
ound observations would be needed, comparing the mech-
nisms of restenosis after balloon angioplasty and stenting
n different HO-1 genotypes.
Restenosis occurs in up to 60% of patients within the first
ear after femoropopliteal interventions with considerable
orbidity and costs (1,7). With increasing numbers of
rocedures performed in any given patient, late sequelae and
he need for costly re-interventions become more frequent
1,2). Identification of this novel genetic risk factor may
elp to predict the risk of restenosis after balloon angio-
lasty. Determination of the HO-1 genotype before a
cheduled intervention may facilitate a targeted use of
djunctive measures for prevention of restenosis-like in-
raluminal brachytherapy or the recently introduced drug-
oated stents (17,41–43). Furthermore, the association
etween HO-1 genotype and inflammatory response after
alloon angioplasty suggests that therapeutic benefit might
lso derive from the use of high-dose anti-inflammatory
edications after the procedure in persons who are genet-cally susceptible.
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irus or adenovirus-mediated delivery of the HO-1 gene,
hich has been successful in animal models (44,45) in
atients undergoing balloon angioplasty, a more practical
nd likely clinically acceptable approach would be induction
f HO-1 with a substance that is accepted for clinical use.
nduced expression of HO-1 suppresses restenosis (6,8).
hile induction of HO-1 is an appealing potential ap-
roach to prevent restenosis, our findings here point out the
ossible difficulty in patients carrying the low HO-1 re-
ponse genotype. In those cases, one may have to devise
ethods of overcoming the low responsiveness; alterna-
ively, one might use one or more of the products produced
y HO-1 action on heme such as CO to prevent restenosis
38). Administration of low doses of CO by inhalation very
arkedly suppresses restenosis. Administration of 250 parts
er million (ppm) for only a single hour before angioplasty
as highly effective at reducing the amount of neointimal
roliferation in rats as measured on day 14 postintervention
38). Other products of HO-1 action on heme, such as
erritin, biliverdin (46), and bilirubin also deserve evaluation
or their effects.
tudy limitations. The association we have shown be-
ween short repeats of the HO-1 gene promoter polymor-
hism and reduced risk of restenosis, as well as the associ-
tion between short repeats and reduced levels of CRP after
ngioplasty, is strong evidence that the association is “real.”
evertheless, the issue of whether this polymorphism in-
eed results in a functional change, or whether it is linked to
gene that exerts the true functional change, remains
nresolved. However, several in vitro and in vivo studies
ave shown directly that HO-1 has benefits on processes
uch as those assayed in this study and have demonstrated
he functional importance of this polymorphism; given the
ombined data, we believe that our hypothesis is strongly
upported (16,38). We do not believe that selection bias
lays a major role, because genetic data was available on
pproximately 95% of patients. Patients with missing ge-
etic data were comparable to the remaining patients (data
ot shown). Information bias is unlikely because outcome
ssessors were blinded to the HO-1 genotype status. Fur-
her, our study is necessarily of an observational nature.
ccordingly, our results may be explained by confounding.
herefore, we tried to control for baseline imbalances
Table 1) by multivariate modeling (Table 2). The possibil-
ty of residual or undetected confounding is small but
annot be ruled out completely.
onclusions. The heme oxygenase-1 gene promoter poly-
orphism is associated with the risk of restenosis six
onths after femoropopliteal balloon angioplasty but not
fter stent implantation. Patients after balloon angioplasty
ith the short (GT)n repeats, which are indicative of a
trong HO-1 response, exhibit a lower postintervention
nflammatory response, as reflected in increases in CRP and
reduced rate of restenosis. The production of carbon
onoxide consequent to HO-1 induction may inhibitascular inflammation, SMC proliferation, and constrictive
ascular remodeling in humans, as has been demonstrated in
xperimental animals.
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